Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 12
Is there any reason to believe that some SSRI derivative couldn't produce the same effects as the more traditional drugs, but acting on the basis of inhibition of reuptake of the various neurotransmitters, rather than direct stimulus? LLY certainly is positioned to know a lot about SSRI's.

It's a provocative approach, assuming all the receptors involved with ADD have been fully characterized.

It's unclear what the abuse potential of such a drug would have, and abandoning all reason, what the DEA / FDA would think, regardless of facts. If the same receptors end up being stomped on via inhibition of reuptake, versus stimulus, the net result would seem to me to be nearly the same.

However, the MAOI's (monoamine oxidase inhibitors), which act also by suppression rather than stimulation, have never been on the BNDD/DEA list. Of course, the MAOIs except for the selective Eldepryl are so dangerous if misused, that may be the reason; even Eldepryl can pose a risk of uncontrolled pressor amines if taken in excess of 10 mg/day along with the risk foods or beverages, or an OTC cold/allergy pill.

The first company that comes out with clinically proven, safe, effective ADD drug that isn't a Controlled Substance is going to be interesting to a lot of people.

RSH.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.